THURMONT, Md., Nov. 8, 2019 /PRNewswire-PRWeb/ -- StageBio
has merged with Alizée Pathology to form the leading provider of
specialized histology, pathology, biomarker development, and
archiving services for the biopharmaceutical, medical device and
contract research industries. StageBio was recently created by the
mergers of Histo-Scientific Research Laboratories (HSRL), Vet Path
Services (VPS) and Tox Path Specialists (TPS), and now includes
Alizée Pathology. StageBio is a portfolio company of Ampersand
Capital Partners.
"Dr. Serge Rousselle, Dr.
Joan Wicks and the Alizée staff
bring unique histopathology capabilities to StageBio. These
services enable us to offer the industry an even broader range of
highly specialized histopathology and imaging services," said Mr.
Thomas Galati, StageBio CEO. "We
have successfully merged HSRL, VPS and TPS, and are excited to add
Alizée's expertise to our growing list of offerings."
Dr. Serge Rousselle, Co-Founder
of Alizée Pathology, commented, "StageBio and Alizée have been
working closely for years, and this union is a natural evolution of
that relationship. The broad client base and services at StageBio,
combined with the specialty expertise at Alizée, are a winning
combination for our clients." The merger adds laboratory space in
Thurmont and Cumberland MD, as well as staff with
experience in specialty medical devices and biomarkers/biologics
that will complement the StageBio team based in Virginia, Massachusetts, Ohio, and Maryland. The combined company now employs 28
board-certified (ACVP) Veterinary Pathologists with a total
employee base of over 150.
About StageBio
StageBio is the leading provider of GLP-compliant research and
preclinical histology, pathology and specimen archiving services
for the biopharmaceutical, medical device and contract research
industries. We provide our customers with a fully integrated
breadth of histopathology services, including tissue analysis,
efficacy determination for new compounds and devices, toxicological
evaluation of products subject to FDA approval, detailed pathology
reporting for GLP studies, medical device pathology and
immunohistochemistry. We operate numerous state-of-the-art sites in
Virginia, Massachusetts, Ohio, and Maryland, with substantial continued
investment in our facility and technology infrastructures to meet
the growing demand for high-quality histopathology services. We are
ideally positioned to deliver on our unified commitment to quality,
scientific integrity and customer service excellence. Additional
information about StageBio is available at
http://www.stagebio.com.
About Alizée Pathology
Founded in 2010, Alizée Pathology is one of the leading
preclinical medical device laboratories in North America. Founded and led by Drs.
Serge Rousselle and Joan Wicks, Alizée provides GLP-compliant
services in support of the development of novel devices and
therapeutics. Alizée's team is comprised of ACVP boarded
Pathologists, PhDs, MDs and highly trained scientists who are
focused on delivering clear, reproducible, and contextual results.
Alizée services the following areas of preclinical medicine and
science: bone repair, interventional medicine, oncology,
inflammatory diseases, immunotherapy, regenerative medicine,
surgical tools, pharmaceuticals and tissue phenotyping. Included
among its staff are 4 board-certified (ACVP) Veterinary
Pathologists, more than 20 highly trained histology technicians and
scientists and a dedicated Quality Assurance (QA) unit. The entire
team is committed to the highest quality work and excellent
customer service. Additional information about Alizée is available
at http://www.alizeepathology.com.
About Ampersand Capital Partners
Founded in 1988, Ampersand is a middle market private equity
firm dedicated to growth-oriented investments in the healthcare
sector. With offices in Boston, MA
and Amsterdam, Netherlands,
Ampersand leverages a unique blend of private equity and operating
experience to build value and drive superior long-term performance
alongside its portfolio company management teams. Ampersand has
helped build numerous market-leading companies across each of its
core healthcare sectors, including Brammer
Bio, Confluent Medical, Genewiz, Genoptix, Talecris
Biotherapeutics and Viracor-IBT Laboratories. Additional
information about Ampersand is available at
http://www.ampersandcapital.com.
SOURCE StageBio